Abstract:Angiogenesis in the tumor microenvironment is the main cause for the insensitivity of tumor cells to chemoradiotherapy. Strategies for increasing the sensitivity of tumor cells to conventional therapies using nanoparticles are limited. In this study, we developed rationally designed microenvironment response nanoparticles with physicochemical and biological features to overcome cisplatin resistance by using decomposition product from Zr-metal-organic framework (MOF) to inhibit the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)/vascular endothelial growth factor (VEGF) pathway in chemoradiotherapy. Cisplatin (CDDP) is encapsulated into Zr-MOF and bovine serum albumin (BSA) is modified into the surface of nanoparticles to create CDDP@Zr-MOF-BSA (abbreviated as CDDP@Zr-MOF), which acts as an excellent radiosensitizer and exhibits microenvironment response, preferable tumor accumulation, high-efficiency inhibition of angiogenesis, and obviously reduced efflux on resistant A549 cells. The rate of angiogenesis inhibition in the combined treatment group is 6-fold higher than that in other control groups. Moreover, CDDP@Zr-MOF not only increases the therapeutic effect remarkably, but also regulates the tumor microenvironment and inhibits the expression of a drug-efflux transporter, namely multidrug resistance-associated protein 1 (MRP1), for reversing drug resistance in A549R cells. Thus, CDDP@Zr-MOF causes synergistic cytotoxicity in A549R cells, and high-efficiency eradication of cisplatin-resistant tumor without regrowth by inhibiting angiogenesis in the tumor microenvironment. The microenvironment responsiveness of CDDP@Zr-MOF provides a multipurpose synergistic approach for treating drug-resistant tumors with chemoradiotherapy.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to overcome the multi - drug resistance of tumor cells in chemotherapy and radiotherapy. Specifically, the researchers developed a nanoparticle based on Metal - Organic Frameworks (MOFs), CDDP@Zr - MOF - BSA, to inhibit the Phosphatidylinositol 3 - Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) signaling pathway, thereby increasing the sensitivity of tumor cells to Cisplatin (CDDP), and enhancing the effects of chemotherapy and radiotherapy by inhibiting angiogenesis. ### Main problem analysis: 1. **Problem of chemotherapy drug resistance**: - Angiogenesis in the tumor microenvironment is the main reason for tumor cells' insensitivity to chemotherapy. - Traditional nanoparticle strategies have limited effectiveness in increasing the sensitivity of tumor cells to conventional treatments. 2. **Multi - drug resistance (MDR) problem**: - Tumor cells develop resistance through multiple mechanisms, such as low cell uptake, high extracellular excretion, increased biotransformation or excretion, etc. - The activation of specific signaling pathways, such as the PI3K/AKT/mTOR/Vascular Endothelial Growth Factor (VEGF) pathway, is closely related to drug resistance. 3. **Combined treatment strategy**: - The researchers designed the CDDP@Zr - MOF - BSA nanoparticle. Through its decomposition products, it inhibits the PI3K/AKT/mTOR/VEGF pathway, reduces drug excretion, and increases the intracellular accumulation of Cisplatin. - In combination with radiotherapy (RT), CDDP@Zr - MOF - BSA can significantly enhance the killing effect on Cisplatin - resistant A549R cells, inhibit angiogenesis, and reverse drug resistance. ### Key mechanisms: - **Inhibition of the PI3K/AKT/mTOR/VEGF pathway**: - The decomposition products of Zr - MOF can effectively inhibit the activation of the PI3K/AKT/mTOR/VEGF pathway, reduce angiogenesis, and decrease the proliferation and invasion abilities of tumor cells. - Inhibiting the expression of VEGF further blocks the downstream signaling pathway and reduces the expression of multi - drug resistance - related proteins (such as MRP1). - **Increasing the intracellular accumulation of Cisplatin**: - The CDDP@Zr - MOF - BSA nanoparticle can effectively deliver Cisplatin, increase its accumulation in tumor cells, reduce drug excretion, and thus enhance the chemotherapy effect. - **Synergistic effect**: - In combination with radiotherapy, CDDP@Zr - MOF - BSA can produce synergistic cytotoxicity, significantly improve the killing effect on Cisplatin - resistant A549R cells, and inhibit tumor regrowth. ### Experimental results: - **Cell experiments**: - The MTT assay shows that the cell proliferation ability in the CDDP@Zr - MOF + RT group is significantly lower than that in other treatment groups. - The colony - formation assay indicates that the colony - formation rate in the CDDP@Zr - MOF + RT group is significantly reduced. - The Transwell assay shows that the cell invasion ability in the CDDP@Zr - MOF + RT group is significantly decreased. - The Hoechst staining and γ - H2AX immunofluorescence results show that the cell apoptosis rate in the CDDP@Zr - MOF + RT group is significantly increased. - **Animal experiments**: - Near - infrared fluorescence imaging (NIRF) and CT imaging show that CDDP@Zr - MOF accumulates well at the tumor site. - After treatment, the tumor volume in the CDDP@Zr - MOF + RT group is significantly reduced, and no obvious toxic side effects are observed. In conclusion, this paper successfully solves the multi - drug resistance problem of tumor cells in chemotherapy and radiotherapy by designing and synthesizing the CDDP@Zr - MOF - BSA nanoparticle, providing a new and effective strategy for treating Cisplatin - resistant tumors.

Inhibiting PI3K/AKT/mTOR signaling by metal-organic frameworks for overcoming multiple drug resistance in chemoradiotherapy

Nanoparticle Delivery of a Triple-Action Pt(iv) Prodrug to Overcome Cisplatin Resistance Via Synergistic Effect

A Biodegradable Nanodrug with Highly Efficient Treatment Effect by Remodeling Tumor Microenvironment and Manipulating Energy Metabolism Against Colorectal Cancer

Reversal of Cisplatin Resistance in Ovarian Cancer by the Multitargeted Nanodrug Delivery System Tf-Mn-MOF@Nira@CDDP

Co-Delivery of VEGF siRNA and THPP via Metal-Organic Framework Reverses Cisplatin-Resistant Non-Small Cell Lung Cancer and Inhibits Metastasis through a MUC4 Regulating Mechanism

Fe3O4‐Incorporated Metal‐Organic Framework for Chemo/Ferroptosis Synergistic Anti‐Tumor via the Enhanced Chemodynamic Therapy

Bifunctional Therapy by Zinc‐Cobalt Bimetal‐Organic Framework with Encapsulated Doxorubicin to Overcome Drug‐Resistance

Copper-Based Metal–Organic Framework Overcomes Cancer Chemoresistance through Systemically Disrupting Dynamically Balanced Cellular Redox Homeostasis

Reshaping Immunosuppressive Tumor Microenvironment Using Ferroptosis/Cuproptosis Nanosensitizers for Enhanced Radioimmunotherapy

Engineering biomimetic nanosystem targeting multiple tumor radioresistance hallmarks for enhanced radiotherapy

Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based “combo” nanoagent together with PD-L1 blockade in reversing multidrug resistance

Tumor microenvironments self-activated cascade catalytic nanoscale metal organic frameworks as ferroptosis inducer for radiosensitization

A Multifunctional Metal-organic Framework Nanosystem Disrupts Redox Homeostasis for Synergistic Therapy

Rationally designed rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance

Surmounting tumor resistance to metallodrugs by co-loading a metal complex and siRNA in nanoparticles

Precision Treatment of Colon Cancer Using Doxorubicin-Loaded Metal-Organic-Framework-Coated Magnetic Nanoparticles

Mitochondrial Dysfunction and Antioxidation Dyshomeostasis-Enhanced Tumor Starvation Synergistic Chemotherapy Achieved Using a Metal-Organic Framework-Based Nano-Enzyme Reactor.

A metal-organic framework (MOF) built on surface-modified Cu nanoparticles eliminates tumors via multiple cascading synergistic therapeutic effects

Erythrocyte Membrane Camouflaged Metal–Organic Framework Nanodrugs for Remodeled Tumor Microenvironment and Enhanced Tumor Chemotherapy

Fe-MOF Nanoplatform: Specifically Overcoming Oxaliplatin Resistance in Colorectal Cancer Through Multifaceted Pathways

Rational design of copper(I)-doped metal-organic frameworks as dual-functional nanocarriers for combined chemo-chemodynamic therapy